Tag: big pharma

Measles vaccine math

Executive summary

One person has died from measles in the last 10 years. Is this a sign that everyone who has not been infected or vaccinated for measles should get vaccinated?

According to all health authorities the answer is yes.

According to your friendly neighborhood misinformation superspreader (me), the answer is a big NO.

Why? Because you’re more likely to die or be seriously injured for life from these shots than benefit from them.

Here’s how the math works out today

Today, the math is obvious: even if the vaccine is 100% effective, we’d save 1 life every 10 years. But in 10 years, injecting 3M kids a year, even with a 1 in 1M death rate from the vaccine (which would be unbelievably safe), we’d have 30 deaths from the vaccine and 1 from the disease. So it’s a no-brainer today to avoid the shots. The same argument can be made for morbidity since if we just look at autism alone, there’s no question. But “science” isn’t able to make this very obvious association and none of the scientists are willing to be publicly challenged.

The math will be different 70 years from now. Should you get it then?

Let’s look at another scenario. Suppose we stop vaccinating kids tomorrow. Then in around 70 years, most everyone will be unvaccinated and we’ll probably have more measles deaths because the NIH will still never let people know about any early treatment with repurposed drugs.

So we should end up with somewhere around 450 deaths a year which is what it was before we had a measles vaccine.

So you have roughly a 1 in a million chance of dying from the measles each year, but your probability of dying from the shot, assuming it is AMAZINGLY safe at 1 death per million, is about the same. It’s a wash.

Generally, you only want to risk a medical intervention when you are absolutely certain that the benefits way outweigh the risks.

Keep reading

Despite progress in data transparency, the FDA still keeps its data secret

History shows that hiding clinical trial data can be deadly.

Vioxx is a well-known example of how the US drug regulator withheld important information about the harms of the drug for over three years, before it was withdrawn from the market and tens of thousands of people died as a consequence.

Numerous initiatives have been launched over the past two decades to improve access to trial data after it became evident that what was reported in peer-reviewed journals was often cherry-picked and misleading.

Eminent scientists have succeeded in gaining access to trial data from the European and Canadian drug regulators, but a recent analysis published in the Journal of Law, Medicine, & Ethics, found that the US FDA still lags behind others when it comes to data transparency.

Keep reading

VENOM NATION: Shocking Number of Americans Have Tried Gila Monster Venom-Based Weight Loss Drugs

A new poll reveals that a shocking percentage of Americans are taking risky Gila monster venom-based weight loss drugs.

According to the latest KFF Health Tracking Poll, one out of every eight adults in the U.S. has used one of the trendy GLP-1 agonist weight loss and diabetes drugs, such as Ozempic and Wegovy.

This class of drugs is based on compounds in the venom of Gila monsters, a type of small Southwestern lizard that happens to be the only venomous type of lizard found in America. Researchers discovered in the early 1990s that they have a special hormone in their venom that can control hunger and slow digestion.

GLP-1 agonists work by imitating a hormone known as GLP-1 that is naturally produced by the body and secreted from the small intestine to trigger the release of insulin while slowing stomach emptying and blocking glucagon secretion. It can also help people feel fuller after eating by impacting the parts of the brain responsible for processing satiety and hunger signals.

The poll found that roughly 6% of all American adults are currently taking one of these medications, which amounts to 15 million people.

Keep reading

MMR Jabs contain massive Endotoxin

Dear Reader, have you found any measurements of Endotoxin in MMR Jabs?

I have been hunting for a while and will add any data you send me to the following finds. Measured Endotoxin in any type of jab is also of great interest.

In a recent post Steve Kirsch showed that Autism was most commonly associated with MMR Jabs.1 I have shown that jabbing the mother with Endotoxin causes Autism in the unborn child, if it survives.2 Look out for MMRV jabs as well.

Now turning my attention to Autism and other damage done to Children from their jabs, starting with MMR.

Keep reading

KA-CHING! Big Pharma Stocks Soar as They Plan Next Vaccine to Solve Bird Flu Pandemic

Major pharmaceuticals had a fantastic week in the global markets amid speculation that they may be ready to develop a vaccine to treat bird flu.

As fears grow around the world over the risk of another pandemic following the detection of avian bird flu in humans, pharmaceutical companies are benefitting from talk that they may be ready to develop another vaccine to stop another pandemic in its tracks.

The Motley Fool reports:

Shares of vaccine stocks Moderna, Novavax, and BioNTech SE rallied this week, appreciating 23.4%, 16.4%, and 9.3%, respectively, through Thursday trading, according to data from S&P Global Market Intelligence.

While these three stocks gained notoriety back in 2020 during the COVID-19 pandemic, it appears this week’s detection of avian bird flu in a second U.S. citizen and the first-ever detection of avian flu in a human in Australia are spurring fears of an outbreak and thus a possible boon for companies that can quickly produce a bird flu vaccine.

A new avian flu, H5N1, was detected in cattle back in March, with one worker in Texas coming down with associated conjunctivitis at that time. But on Wednesday this week, a second U.S. dairy worker in Michigan tested positive for the avian flu as well. That same day, an Australian dairy worker also tested positive for avian flu, marking the first-ever human case of avian flu in that country.

The discoveries spurred fears of an outbreak. That same day, the Assistant Secretary of Preparedness and Response at the Department of Health and Human Services, Dawn O’Connell, noted that Moderna and Pfizer, which partnered with BioNTech on the COVID-19 mRNA vaccine, were in talks over a potential mRNA vaccine program for the new avian flu.

As has been extensively reported by The Gateway Pundit, major pharmaceuticals including Pfizer, Moderna and AstraZeneca made billions in profits for their shareholders after developing a series of vaccines intended to treat COVID-19.

Keep reading

Further Ethical Concerns on a Recent Self-Amplifying RNA Vaccine Study

I called for the ongoing study to be ceased given the mass safety signal pointed out by The McCullough Foundation.

Today, I outline further ethical flaws:

  1. Informed Consent:
  • Participants must be fully informed about the novel nature of srRNA technology, including potential unknown long-term effects. Ensuring that informed consent is genuinely informed is critical.
  • Detailed information about the potential risks and benefits, including those observed in preclinical and early-phase clinical trials, should be provided.
  • Since the long-term risks are unknown, this seems impossible.
  1. Conflict of Interest:
  • The authors are employees of Replicate Bioscience Inc., which raises concerns about bias. The review should disclose how the conflict of interest was managed.
  • Independent oversight or review by third-party experts who do not stand to benefit financially from the vaccine should be conducted.
  1. Safety Monitoring:
  • Continuous monitoring for adverse effects is essential, especially given the novel nature of srRNA vectors.
  • Clear protocols for reporting and managing adverse events, including long-term follow-up, and plans to mitigate the ill-health effects of AEs and SAEs, must be transparent and outlined up-front.
  1. Methodological Issues

Cause of Death Determination:

  • Accurate determination of causes of death in clinical trials is crucial. There should be a standardized protocol for post-mortem analysis to ascertain whether deaths are related to the vaccine or underlying conditions. Doctors working for the company determining that the vaccine was not the cause of death is insufficient: it’s a novel vaccine: how do they know they are not confusing deaths from COVID19 with deaths from vaccines? PCR is known to be fraught with errors in this context. How do they know that the vaccine does not interact with COVID19 infection and increase mortality?
  • Independent medical reviews of cause-of-death determinations can mitigate bias.

Manufacturing Quality:

  • The article mentions impurities from poor manufacturing that lead to systemic inflammatory responses. To minimize such risks, strict quality control measures and validation processes should be in place.
  • Detailed documentation and transparency regarding manufacturing practices are essential to ensure reproducibility and safety.

Keep reading

What’s the Difference Between Big Tobacco and Big Pharma?

The psychiatric drug industry and big tobacco share striking similarities in their tactics, particularly when it comes to downplaying the risks associated with their products and targeting vulnerable populations like youth. The psychiatric community has gotten away with pretending it is based in science and medicine to sell its snake oil, while the tobacco industry wasn’t so lucky.

A key difference lies in the government’s stance – while tobacco companies face increasing regulations and warnings, the psychiatric drug industry enjoys substantial government support and promotion despite the existence of black box warnings on many of their medications. Both industries have a history of misleading marketing practices and minimizing potential harms.

Big tobacco companies notoriously concealed evidence linking smoking to lung cancer and other diseases for decades. Similarly, psychiatric drug manufacturers have been accused of selectively publishing favorable trial data and underreporting adverse effects.

Despite black box warnings – the FDA’s strongest safety alert – on many psychiatric medications, big pharma’s marketing often portrays an overly rosy picture. A prime example is antidepressants carrying a black box warning about increased suicidality risk in youth. Yet, these drugs continue to be heavily promoted, with limited emphasis on this severe side effect. Worse yet, antidepressants are not approved for under 18’s and still they are prescribed off-label to the age group in increasing numbers. Atypical antipsychotics like Seroquel and Zyprexa also bear a black box warning about increased mortality risk in elderly dementia patients, but their use in this vulnerable population remains widespread.

Moreover, both industries have targeted youth, securing future customers through early exposure and addiction. Big tobacco’s calculated efforts to market to adolescents are well-documented. Many of us remember getting boxes of candy cigarettes as children. The tips of the candy cigarettes were even painted red to simulate they were lit. Likewise, the psychiatric drug industry has been criticized for driving the dramatic rise in childhood psychiatric diagnoses and medication use, despite limited long-term safety data.

However, a crucial difference emerges in the government’s approach. Tobacco companies face intense scrutiny, with advertising restrictions, graphic health warnings on packaging, and mounting litigation. In contrast, the psychiatric drug industry enjoys considerable government financial support, 10.8 billion in the 2024 budget, and lack of stringent oversight.

Keep reading

Many countries have reached the point of over-medication

The fact that hospital waiting lists are increasing all the time, that the amount of sick leave taken by working men and women seems to rise each year, that mental illnesses are getting commoner every time statistics are brought up to date, that the incidence of heart disease seems to be on the increase, that there is a massive increase in the amount of pollutant-inspired illness, that 80 per cent of modern cancers are thought to be caused by chemicals of one sort or another, and that the number of health professionals needed to cope with all the sickness is increasing rapidly, seem to suggest that medical research has had relatively little effect on the morbidity rates or upon the quality of life at any time in the last century.

In addition, there is evidence that medical research has actually detracted from the quality of life, causing ethical problems and using funds which could be better used on projects more likely to contribute to good health.

Indeed, there is not only evidence for the uselessness of much medical research: there are also sound indications that many developed countries have reached a point of over-medication which is harmful to health. As Dr. Vernon Coleman pointed out in his book ‘Coleman’s Laws’, if a patient has two conditions – two diseases – there is a very good chance that one of those diseases was caused by the treatment for the other.

Writing in the Journal of Human Resources, an American researcher, Charles T. Stewart, has shown that life expectation is approximately the same in countries with between 4 and 16 doctors per 10,000 people. It is a certain fact that while the number of patients treated by doctors is increasing in numerical terms, the number saved as a percentage of those who could be saved is falling dramatically.

There is a savage irony in the fact that we have now reached the point where, on balance, well-meaning doctors in general practice, and highly trained, well-equipped specialists working in hospitals, may do more harm than good. The epidemic of iatrogenic disease which has always scarred medical practice has been steadily getting worse and today most of us would, most of the time, be better off without a medical profession.

Keep reading

Woman With Vaccine Injury in Clinical Trial Sues AstraZeneca

An American woman who suffered an injury from AstraZeneca’s COVID-19 vaccine sued the company on May 13, alleging the company breached a contract by not paying for the medical care she requires to deal with the injury.

“They left us no choice,” Brianne Dressen, a preschool teacher in Utah, told The Epoch Times in an email.

Ms. Dressen has paid tens of thousands of dollars to drugs to treat the nervous system disorder and other issues she’s experiencing, according to the complaint, filed in federal court in her home state.

Ms. Dressen chose to participate in AstraZeneca’s clinical trial in 2020 because she wanted to help the company develop its COVID-19 vaccine. The consent form she signed stated in part that AstraZeneca would “cover the costs of research injuries” and “pay the costs of medical treatment.”

“With these reassurances should something go wrong, Bri signed the form, rolled up her sleeve, and let the drug company inject the experimental product into her arm. Her mind was at peace, as Bri believed she was doing the right thing for her country, her students, and her family,” the suit states.

Ms. Dressen soon started experiencing problems, including blurred vision, tinnitus, and vomiting. She later became extremely sensitive to light and suffered spikes in her heart rate.

Keep reading

Chemical tweaks to a toad hallucinogen turns it into a potential drug

It is becoming increasingly accepted that classic psychedelics like LSD, psilocybin, ayahuasca, and mescaline can act as antidepressants and anti-anxiety treatments in addition to causing hallucinations. They act by binding to a serotonin receptor. But there are 14 known types of serotonin receptors, and most of the research into these compounds has focused on only one of them—the one these molecules like, called 5-HT2A. (5-HT, short for 5-hydroxytryptamine, is the chemical name for serotonin.)

The Colorado River toad (Incilius alvarius), also known as the Sonoran Desert toad, secretes a psychedelic compound that likes to bind to a different serotonin receptor subtype called 5-HT1A. And that difference may be the key to developing an entirely distinct class of antidepressants.

Uncovering novel biology

Like other psychedelics, the one the toad produces decreases depression and anxiety and induces meaningful and spiritually significant experiences. It has been used clinically to treat vets with post-traumatic stress disorder and is being developed as a treatment for other neurological disorders and drug abuse. 5-HT1A is a validated therapeutic target, as approved drugs, including the antidepressant Viibryd and the anti-anxiety med Buspar, bind to it. But little is known about how psychedelics engage with this receptor and which effects it mediates, so Daniel Wacker’s lab decided to look into it.

The researchers started by making chemical modifications to the frog psychedelic and noting how each of the tweaked molecules bound to both 5-HT2A  and 5-HT1A. As a group, these psychedelics are known as “designer tryptamines”—that’s tryp with a “y”, mind you—because they are metabolites of the amino acid tryptophan.

The lab made 10 variants and found one that is more than 800-fold selective about sticking to 5-HT1A as compared to 5-HT2A. That makes it a great research tool for elucidating the structure-activity relationship of the 5-HT1A receptor, as well as the molecular mechanisms behind the pharmacology of the drugs on the market that bind to it. The lab used it to explore both of those avenues. However, the variant’s ultimate utility might be as a new therapeutic for psychiatric disorders, so they tested it in mice.

Keep reading